《新股消息》心瑋醫療科技(06609.HK)今日起招股 入場費8,636.16元
心瑋醫療科技(06609.HK)公佈招股詳情,計劃發售660.19萬股H股,當中10%在港公開發售,招股價介乎160元至171元,每手50股,入場費8,636.16元。由今日(10日)至本週五(13日)公開招股,預計於8月20日上市。高盛及中金爲聯席保薦人。
該公司引入10名基石投資者,包括清池資本、博裕資本等,合共認購6,600萬美元股份。
以招股價中位數165.5元計,公司預計集資所得款項淨額爲9.81億元,當中約45.3%預期將分配至核心產品;約39.9%分配至管線內的其他在研產品;約4.8%用於爲透過內部研究提升研發能力及持續擴充產品組合提供資金;10%作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.